Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. - Wikidata - wikimedia - TriplyDB

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.

http://www.wikidata.org/entity/Q42638752

about

Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin Systematic reviews of treatment for inflammatory demyelinating neuropathy The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy Chronic inflammatory demyelinating polyneuropathy Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.Neurologic indications for therapeutic plasma exchange: an update.Neurologic indications for therapeutic plasma exchange: 2011 update.Neurologic indications for therapeutic plasma exchange: 2013 update.Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Pathogenesis and treatment of immune-mediated neuropathies.An update on the management of chronic inflammatory demyelinating polyneuropathy.Therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review.Autoimmune neuromuscular disorders in childhood Mycophenolate mofetil and neurological diseases.A review of the medical management of chronic inflammatory demyelinating polyradiculoneuropathy.Therapeutic apheresis in neurology critical care.Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.Chronic inflammatory demyelinating polyneuropathy: a treatment protocol proposal.Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Outcome of Guillain-Barre syndrome patients with respiratory paralysis.Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function.Chronic inflammatory demyelinating polyradiculoneuropathy: a role for haematopoietic stem cell transplantation?Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.Modified Atkins diet induces subacute selective ragged-red-fiber lysis in mitochondrial myopathy patients.Clinical consequences of reduced dosing schedule during treatment of a patient with Pompe's disease.Evidence-based treatment of chronic immune-mediated neuropathies.Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.Plasmapheresis for neurological disorders.Therapeutic Plasma Exchange in Neurologic Diseases: An Experience with 91 Patients in Seven Years.Treatment in inflammatory neuropathies.

P2860

Q24187755-AA4DF427-7462-4EE8-A478-CA4D57995AFC Q24200900-A3743655-E2B8-4835-8DE2-B1FC5B902AD8 Q24201954-5DAFBE39-5476-4539-B68D-0E77E0BC6951 Q24236599-0B33E8F3-7886-4AE3-BDBD-A330426F6128 Q24630092-BC4B39CB-185A-4860-91A1-570565FE523C Q24670327-780A56D6-DB14-4389-AD79-A24767DAA1BA Q24676037-35F21B5F-0B6C-4550-B999-6332E5BBF0A6 Q26743993-094FFBC1-C3F5-4144-8641-598C0521798C Q26823910-2077C90A-3A86-4BA7-B2CA-6669FA56172F Q26864907-DDA303B3-C387-44B1-867D-67BC64FCFB74 Q28081570-BC98DD27-2219-4E93-964C-270D5D00F329 Q28384089-2181DAE7-78EF-4B90-B3C4-6B8668FD5BB7 Q30276550-5714D662-8423-4B86-9649-6A4A2AD52273 Q30397454-F0508405-5275-462A-8928-C227443A6B57 Q30454297-F8943BEA-1398-410A-BAA1-A92F10AB6887 Q30455391-24896DD0-575F-430F-8305-A02E9895303A Q30458271-7822327B-78F6-422C-8576-7F56CAD3F3EA Q34109136-5DCE25D6-ECF8-4E29-8ECC-41ACA77F5C68 Q34122035-22B9A63A-CB42-448B-9A9B-C7D5299DD4A4 Q34409385-147E334E-1133-4314-BAEB-E53F6324D4BA Q34645179-1A920D10-10D7-42B1-85AA-A43BBEF9C535 Q35089149-7658C620-EC0B-4B13-B953-C5FACC20ED7D Q35512273-9E890430-C6F1-4F01-B1A0-12DD66106528 Q36085865-98C71F96-35D4-486A-929C-7C02A2974C29 Q36150688-A4427948-1BB0-42D0-9839-BA19ED561DBC Q36215377-FAAF36ED-6D86-44BF-8E82-9D97DF5D025A Q36365583-FB83BDA4-6552-4DF0-9730-74AB08EB66FC Q36419576-32085D49-2C3A-4387-81A3-2B275AA4B5D6 Q36484438-5B93C59F-9722-4F03-8255-0E65D19A11E3 Q36954790-7421A73E-4639-4230-BE3F-6797681A12E6 Q37180600-AAA7EAEF-2924-460E-8F52-E1185C6BC5F1 Q37311081-66023DF8-B9A7-4CE9-A380-7AB3CAD66272 Q37329516-AACD7F24-BAA8-4EFF-B331-CA33D3A3090F Q37386981-43257799-50D7-4550-9D89-9164F4992A87 Q37414501-65238B2D-E4B7-4B23-B7B7-C59E7D4DA852 Q37550515-A6998B86-40C8-465E-9368-28063C5985DA Q37557375-1993D393-B023-4755-9DA3-2D42E1AEB820 Q37600865-BBE9EAB8-E4BD-40E0-AA0B-D3AA78C625EA Q37725863-C1FCA5E3-25C5-4EA7-89AC-2F1797150990 Q37733512-6D86AA2F-E16E-4538-A86A-6494E19AA1C8

P2860

Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study.

http://www.wikidata.org/entity/Q42638752

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Plasma-exchange therapy in chr ...... -controlled, cross-over study.

@en

Plasma-exchange therapy in chr ...... -controlled, cross-over study.

@nl

type

label

Plasma-exchange therapy in chr ...... -controlled, cross-over study.

@en

Plasma-exchange therapy in chr ...... -controlled, cross-over study.

@nl

prefLabel

Plasma-exchange therapy in chr ...... -controlled, cross-over study.

@en

Plasma-exchange therapy in chr ...... -controlled, cross-over study.

@nl

P1433

Q42638752-306C6B91-86BC-4C19-8CB3-AC0BD467E25C

P1476

Q42638752-72C8BA74-60FE-43C6-AF55-EE5512178E7F

P2093

Q42638752-13CE1C6E-A181-46B3-8010-C3DB48FF1167

Q42638752-3497AA29-B83B-475B-9E59-29E6738F402B

Q42638752-373E7CC4-FBFE-47E4-ACC9-7B5D8BCC4684

Q42638752-7D5C495A-EB7E-4067-93F8-BAD847878180

Q42638752-8205A835-2291-4B95-86C7-9979AD973525

Q42638752-8520FE41-ADA1-4D8B-AA0C-E0189497D1D7

Q42638752-92D5F1CA-D8B4-4BC5-BBC5-793A18FEE620

Q42638752-CCA259CE-214B-4981-9BF5-E993C83EE2AD

Q42638752-FC74C08D-A7C9-4038-8D1A-714E1DF12E0B

P304

Q42638752-94990273-4F4A-4885-B078-C6F94CB05B92

P31

Q42638752-F2009C67-6E3E-433E-98E0-884A9C444AA0

P356

Q42638752-19736695-969A-4DA1-8533-04D4FE661F2C

P407

Q42638752-CAFFCB57-EAA7-49AB-AFA5-6600FE2FB44C

P478

Q42638752-8DC82207-5CDA-452C-959C-16DE11E7544B

P577

Q42638752-E60BFF39-6310-462A-9C29-EB0344CC7F69

P5875

Q42638752-21DABE8D-8240-4B09-BCFE-83369267AA15

P698

Q42638752-FC7647D9-485A-4F46-B9DA-A2CEEB56D2F9

P921

Q42638752-B19C36C9-A102-4392-868D-75A032923999

P356

P1433

P1476

Plasma-exchange therapy in chr ...... -controlled, cross-over study.

@en

P2093

Benstead T

http://www.w3.org/2001/XMLSchema#string

Bolton CF

http://www.w3.org/2001/XMLSchema#string

Bril V

http://www.w3.org/2001/XMLSchema#string

Chalk C

http://www.w3.org/2001/XMLSchema#string

Feasby TE

http://www.w3.org/2001/XMLSchema#string

Hahn AF

http://www.w3.org/2001/XMLSchema#string

Pillay N

http://www.w3.org/2001/XMLSchema#string

Shumak K

http://www.w3.org/2001/XMLSchema#string

Vandervoort MK

http://www.w3.org/2001/XMLSchema#string

P304

1055-1066

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/119.4.1055

http://www.w3.org/2001/XMLSchema#string

P407

P478

119 ( Pt 4)

http://www.w3.org/2001/XMLSchema#string

P577

1996-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14392405

http://www.w3.org/2001/XMLSchema#string

P698

8813270

http://www.w3.org/2001/XMLSchema#string

P921